A detailed history of Lindbrook Capital, LLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 546 shares of VKTX stock, worth $28,714. This represents 0.0% of its overall portfolio holdings.

Number of Shares
546
Previous 265 106.04%
Holding current value
$28,714
Previous $14,000 142.86%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

BUY
$49.84 - $70.47 $14,005 - $19,802
281 Added 106.04%
546 $34,000
Q2 2024

Jul 31, 2024

SELL
$47.39 - $80.2 $4,170 - $7,057
-88 Reduced 24.93%
265 $14,000
Q1 2024

Apr 25, 2024

BUY
$17.4 - $94.5 $4,837 - $26,271
278 Added 370.67%
353 $28,000
Q4 2023

Jan 31, 2024

SELL
$9.24 - $19.64 $1,386 - $2,946
-150 Reduced 66.67%
75 $1,000
Q3 2023

Oct 25, 2023

BUY
$10.92 - $16.0 $567 - $832
52 Added 30.06%
225 $2,000
Q1 2023

Apr 26, 2023

BUY
$8.08 - $17.33 $1,397 - $2,998
173 New
173 $2,000
Q1 2022

Apr 21, 2022

SELL
$3.0 - $4.88 $22,500 - $36,600
-7,500 Closed
0 $0
Q4 2021

Jan 18, 2022

BUY
$4.6 - $6.72 $31,532 - $46,065
6,855 Added 1062.79%
7,500 $35,000
Q1 2021

Apr 28, 2021

SELL
$5.74 - $9.67 $941 - $1,585
-164 Reduced 20.27%
645 $4,000
Q4 2020

Jan 27, 2021

BUY
$5.3 - $6.71 $869 - $1,100
164 Added 25.43%
809 $5,000
Q3 2019

Oct 31, 2019

BUY
$6.55 - $8.6 $4,224 - $5,547
645 New
645 $4,000
Q2 2019

Jul 24, 2019

SELL
$7.67 - $10.63 $10,738 - $14,882
-1,400 Closed
0 $0
Q1 2019

Apr 23, 2019

SELL
$7.58 - $9.94 $25,772 - $33,796
-3,400 Reduced 70.83%
1,400 $13,000
Q4 2018

Feb 07, 2019

BUY
$7.16 - $16.21 $34,368 - $77,808
4,800 New
4,800 $36,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $4.03B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Lindbrook Capital, LLC Portfolio

Follow Lindbrook Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.